Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Stem Cell Rev Rep ; 20(1): 206-217, 2024 01.
Artículo en Inglés | MEDLINE | ID: mdl-37922107

RESUMEN

Strategies to improve hematopoietic stem and progenitor cell (HSPC) mobilization from the bone marrow can have a pivotal role in addressing iatrogenic bone-marrow insufficiency from chemo(radio)therapy and overcoming peripheral blood stem cell transplantation (PBSCT) limitations such as insufficient mobilization. Granulocyte-colony stimulating factor (G-CSF) represents the standard mobilization strategy for HSPC and has done so for more than three decades since its FDA approval. Its association with non-G-CSF agents is often employed for difficult HSPC mobilization. However, obtaining a synergistic effect between the two classes is limited by different timing and mechanisms of action. Based on our previous in vitro results, we tested the mobilization potential of human chorionic gonadotropin (HCG), alone and in combination with G-CSF in vivo in a murine study. Our results show an improved mobilization capability of the combination, which seems to act synergistically in stimulating hematopoiesis. With the current understanding of the dynamics of HSPCs and their origins in more primitive cells related to the germline, new strategies to employ the mobilization of hematopoietic progenitors using chorionic gonadotropins could soon become clinical practice.


Asunto(s)
Trasplante de Células Madre de Sangre Periférica , Humanos , Animales , Ratones , Factor Estimulante de Colonias de Granulocitos/farmacología , Modelos Animales de Enfermedad , Células Madre Hematopoyéticas/metabolismo , Gonadotropina Coriónica/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA